|
Summary Information: NLS Pharmaceutics Ltd. Ordinary Shares NASDAQ:NLSP |
  admin@troach.net |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage pharmaceutical company led by an experienced\r management team with a track record of developing and repurposing product candidates to treat rare\r and complex central nervous system disorders. The Company’s lead product candidate, Quilience® is a\r proprietary controlled release formulation of mazindol (mazindol CR), and is being developed for the\r treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2\r agonist, which was used for many yearsto treat patients diagnosed with narcolepsy in compassionate use\r programs. NLS completed a phase 2 study in the U.S. evaluating mazindol CR in adult subjects with ADHD.\r The study met all primary and secondary endpoints and was well-tolerated. Quilience® has received\r Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.
__The following are links to various summary and news pages for __NLS Pharmaceutics Ltd. Ordinary Shares [ NLSP ]. __Note: Some Links might not have information for the company. |
|